473-84-7

Basic information

• Product Name: 2-hydroxycyclopentanone
• Synonyms: 2-Hydroxycyclopentanone; cyclopentanone, 2-hydroxy-
• CAS NO: 473-84-7
• Molecular Formula: C₅H₈O₂
• Molecular Weight: 100.1158
• Mol File: 473-84-7.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 210°C at 760 mmHg
• Flash Point: 83.3°C
• Density: 1.217g/cm³
• Vapor Pressure: 0.0451mmHg at 25°C
• Refractive Index: 1.514
• CAS DataBase Reference: 2-hydroxycyclopentanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxycyclopentanone(473-84-7)
• EPA Substance Registry System: 2-hydroxycyclopentanone(473-84-7)

Safety Data

• Hazardous Substances Data: 473-84-7(Hazardous Substances Data)

Usage

Description

2-Hydroxycyclopentanone, also known as 2-HCP, is a cyclic ketone with a molecular formula of C5H8O2. It features a hydroxyl group attached to the second carbon atom in the cyclopentanone ring. This clear, colorless liquid has a slightly sweet aroma and is soluble in both water and organic solvents.

Uses

Used in Pharmaceutical Synthesis:
2-Hydroxycyclopentanone is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to be a key component in the creation of a wide range of medications and other chemical products.
Used in Antioxidant and Anti-Inflammatory Drug Development:
Due to its potential antioxidant and anti-inflammatory properties, 2-hydroxycyclopentanone is used in the development of new drugs for medical and pharmaceutical applications. Its ability to combat oxidative stress and reduce inflammation makes it a promising candidate for treating conditions that involve these processes.

Upstream product

• 1119-40-0 Dimethyl glutarate 
• 5057-98-7 cis-1,2-cyclopentanediol 
• 128994-14-9 (7R,9R)-7,9-dimethyl-6,10-dioxaspiro<4.5>decane 
• 111-30-8 Glutaraldehyde 
• 20520-67-6 (+/-)-cis-1-acetoxy-2-hydroxycyclopentane 
• 37854-32-3 rel-(1R,2S)-cyclopentane-1,2-diol diacetate 
• 52789-75-0 2-acetoxycyclopentanone 
• 5057-99-8 trans-cyclopentane-1,2-diol 
• 99440-98-9 2-hydroxycyclopentanone 
• 120-92-3 cyclopentanone 
• 930-46-1 (1R,2R)-cyclopentane-1,2-diol 
• 1402704-77-1 C₁₃H₁₁NO₃ 
• 694-27-9 5-bromo-cyclopent-2-en-1-one 
• 930-30-3 cyclopent-2-enone 

Downstream Products

• 5057-98-7 cis-1,2-cyclopentanediol 
• 99493-88-6 (R)-2-hydroxycyclopentanone 
• 147333-12-8 (2S)-2-hydroxycyclopentan-1-one 
• 63261-45-0 (S,S)-cyclopentane-1,2-diol 
• 59058-16-1 2-(benzoyloxy)cyclopentanone 
• 110-94-1 1,5-pentanedioic acid 
• 605653-10-9 C₁₃H₂₄O₄ 
• 339362-68-4 2-aminocyclopentanone 
• 1374422-09-9 (2R)-2-hydroxy-2-[(R)-hydroxy(4-nitrophenyl)methyl]cyclopentanone 
• 1374422-04-4 (2R)-2-hydroxy-2-[(S)-hydroxy(4-nitrophenyl)methyl]cyclopentanone 

Relevant articles and documents

Novel hypervalent iodine catalyzed synthesis of α-sulfonoxy ketones: Biological activity and molecular docking studies

The novel di((camphorsulfonyl)oxy)iodo]benzene (DCIB) was synthesized from [Bis(trifluoroacetoxy)iodo]benzene in the mild conditions. The α-sulfonoxylation of various ketones with novel hypervalent iodine was reported in excellent yield. α-Hydroxyketones

Site-Selective and Product Chemoselective Aliphatic C-H Bond Hydroxylation of Polyhydroxylated Substrates

Site-selective and product chemoselective aliphatic C-H bond oxidation of 1,2-diols and of polyhydroxylated substrates using iron and manganese catalysts and hydrogen peroxide as terminal oxidant is described. The reaction capitalizes on the use of fluorinated alcohol solvents such as 2,2,2-trifluoroethanol (TFE) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), which exert a strong polarity reversal in the hydroxyl moieties of 1,2-diols via hydrogen bonding, in turn translating into a strong deactivation of proximal C-H bonds against a HAT initiated oxidation by the putative high-valent and electrophilic metal-oxo species. As a result, site-selective and product chemoselective oxidation of complex polyfunctional molecules such as steroids, sugars, and pharmaceuticals is described, where exclusive or predominant C-H bond hydroxylation at a remote and nonactivated site takes place. The current report discloses HAT initiated hydroxylations in fluorinated alcohol solvents as methods displaying orthogonal chemoselectivity to contemporary alcohol oxidations providing a useful tool for synthetic planning in densely functionalized molecules.

Ligustrazine-fused cyclic compound and medicine composition thereof, as well as application in medicine thereof

The invention discloses a ligustrazine-fused cyclic compound and a medicine composition thereof and application in a medicine. The ligustrazine-fused cyclic compound has the following structural general formula I: as shown in the specification. The medicine composition is a medicinal active component for the ligustrazine-fused cyclic compound and a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, a medium or a combination thereof; the ligustrazine-fused cyclic compound and the medicine composition can be used for preventing or treating cardiovascular and cerebrovascular diseases, digestive system diseases, respiratory diseases, the alzheimer's disease, kidney diseases and complications of the above-mentioned diseases due to thrombus and excessive free radicals. The ligustrazine-fused cyclic compound disclosed by the invention has an extremely good inhibition effect on in vitro ADP (adenosine diphosphate)-induced platelet aggregation; meanwhile, compared with the pharmacokinetic property of ligustrazine serving as a female parent, the pharmacokinetic property of the ligustrazine-fused cyclic compound in the body of a rat is obviously improved.